Masson R, Titievsky L, Corley DA, et al. - Among patients diagnosed with different types of cancer (excluding non-melanoma skin cancer) in the pretyrosine kinase inhibitor (TKI) and bevacizumab treatment era, researchers quantified the incidence rates of cardiovascular outcomes. Using data from the Kaiser Permanente Northern California population of cancer patients, a retrospective cohort study was performed. According to the type of cancer and the number of cardiovascular risk factors, event rates were calculated. The research involved about 165,000 people with a broad variety of tumor types. Cardiovascular risk factors like diabetes mellitus, dyslipidemia, hypertension, and smoking were common. Incident hypertension, heart failure, and the acute coronary syndrome were the most frequent adverse outcomes. For increasing numbers of cardiovascular risk factors, the incidence of the acute coronary syndrome, heart failure, and ischemic stroke increased. Cardiovascular risk factors and outcomes are very common in a population of patients with cancer not exposed to TKIs, regardless of cancer type. These data can inform the assessment of potential cardiovascular excess risks from new interventions.